SCHEMBL2970263

SCHEMBL2970263

CC(C)Nc1ncnc2oc(I)c(-c3ccccc3)c12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.59
AURKA O14965 5/20 0.57
LCK P06239 3/20 0.53
TNK2 Q07912 3/20 0.53
JAK2 O60674 1/20 0.53
SRC P12931 1/20 0.53
KDR P35968 1/20 0.53
ZAP70 P43403 1/20 0.53
JAK3 P52333 1/20 0.53
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CHEK1 O14757 2/20 0.45
MAP2K1 Q02750 1/20 0.45
RAD52 P43351 1/20 0.44
ABL1 P00519 1/20 0.42
LYN P07948 1/20 0.42
BTK Q06187 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961274 0.84 EGFR (0.59) EGFRAURKALCKTNK2JAK2
SCHEMBL5251235 0.80 AURKA (0.58) AURKALCKTNK2KDRKMT2A
SCHEMBL2975737 0.75 TNK2 (0.47) EGFRAURKATNK2SRCKMT2A
SCHEMBL6259495 0.74 EGFR (1.00) EGFRAURKALCKTNK2JAK2
SCHEMBL2976978 0.73 EGFR (0.61) EGFRAURKALCKTNK2JAK2
SCHEMBL2977223 0.73 TNK2 (0.79) LCKTNK2KDRJAK3ABL1
SCHEMBL2977217 0.73 TNK2 (0.79) LCKTNK2KDRJAK3ABL1
SCHEMBL2966704 0.73 AURKA (0.50) EGFRAURKALCKTNK2JAK2
SCHEMBL2970697 0.72 TNK2 (0.73) EGFRAURKALCKTNK2JAK2
SCHEMBL2249401 0.71 AURKA (0.83) EGFRAURKALCKTNK2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US claimed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP claimed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US claimed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO claimed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP disclosed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US disclosed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 EGFR 837/4885AURKA 1528/4885LCK 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.